AI English summary of an SEC filing — figures as filed
Illumina ILMNIllumina said revenue for 2025 was $2,100 million, down 4% from $2,188 million in 2024. The company cited a decrease in GRAIL service and other revenue as a result of the Spin-Off in Q2 2024 and a decrease in Core Illumina service and other revenue as primary factors.
Key points
AI summaryIllumina said revenue for 2025 was $2,100 million, down 4% from $2,188 million in 2024. The company cited a decrease in GRAIL service and other revenue as a result of the Spin-Off in Q2 2024 and a decrease in Core Illumina service and other revenue as primary factors.
Illumina said income from operations for 2025 was $378 million, compared to a loss from operations of $1,749 million in 2024, with a decrease in operating expense of $2,137 million as the primary driver. The company cited the goodwill and intangible asset impairment of $1,886 million recognized for GRAIL in 2024 as the background.
Illumina said net cash provided by operating activities for 2025 was $474 million and used $566 million in financing activities, of which $570 million was used for share repurchases.
Illumina said on June 22, 2025 it entered into an agreement with Standard BioTools to acquire SomaLogic and other specified assets for $350 million in cash, with potential milestone payments of up to $75 million and royalty streams. The company said it expects the transaction to close in the first half of 2026.
Key figures
Quarter ended June 29, 2025
- Revenue
- $1.1B
- Operating income
- $214M
- Net income
- $235M
- EPS
- $1.49
- Gross profit
- $695M
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
2025 Revenue $2,100 million
Illumina said revenue for 2025 was $2,100 million, down 4% from $2,188 million in 2024. The company cited a decrease in GRAIL service and other revenue as a result of the Spin-Off in Q2 2024 and a decrease in Core Illumina service and other revenue as primary factors.
Source · Based on the MD&A text of the filing
Operating Income $378 million and Operating Expense Decrease
Illumina said income from operations for 2025 was $378 million, compared to a loss from operations of $1,749 million in 2024, with a decrease in operating expense of $2,137 million as the primary driver. The company cited the goodwill and intangible asset impairment of $1,886 million recognized for GRAIL in 2024 as the background.
Source · Based on the MD&A text of the filing
2025 Cash Flow and Share Repurchases
Illumina said net cash provided by operating activities for 2025 was $474 million and used $566 million in financing activities, of which $570 million was used for share repurchases.
Source · Based on the MD&A text of the filing
SomaLogic Acquisition Agreement
Illumina said on June 22, 2025 it entered into an agreement with Standard BioTools to acquire SomaLogic and other specified assets for $350 million in cash, with potential milestone payments of up to $75 million and royalty streams. The company said it expects the transaction to close in the first half of 2026.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…